Product Name: Chlortetracycline Premix

Generic Name: Chlortetracycline

Description: This product is a brown or brownish-brown granule (powder) with no lumps or mold.

Specification: 1000g: 150g (1.5 billion units); 1000g: 200g (2 billion units)

Pharmacological Action: This product belongs to the tetracycline class of drugs, mainly inhibiting the protein synthesis of sensitive microorganisms. It has a broad spectrum of antibacterial activity, and can inhibit Gram-positive bacteria, Gram-negative bacteria, spirochetes, rickettsia, mycoplasma, chlamydia, and some protozoa. Chlortetracycline mainly binds to the A site of the 30S subunit of microorganisms, interfering with the binding of aminoacyl-tRNA to the 30S subunit, preventing aminoacyl-tRNA from entering the codon on the mRNA, and inhibiting the elongation of the peptide chain during protein synthesis. Chlortetracycline can also prevent the release of the synthesized protein peptide chain.

Indications: It is used to treat post-weaning piglet diarrhea, swine asthma, and proliferative enteritis.

Approval Number: Veterinary Drug License No. 050374651, Veterinary Drug License No. 050374652.

brief introduction

Chlortetracycline Premix is a veterinary drug used to treat post-weaning piglet diarrhea, swine asthma, and proliferative enteritis. It contains chlortetracycline as its main active ingredient, which belongs to the tetracycline class of drugs. Chlortetracycline acts by inhibiting the protein synthesis of sensitive microorganisms, thereby preventing their growth and multiplication.

The product is available in two different specifications: 1000g: 150g (1.5 billion units) and 1000g: 200g (2 billion units). It is a brown or brownish-brown granule (powder) with no lumps or mold.

Chlortetracycline has a broad spectrum of antibacterial activity and can inhibit Gram-positive bacteria, Gram-negative bacteria, spirochetes, rickettsia, mycoplasma, chlamydia, and some protozoa. It mainly binds to the A site of the 30S subunit of microorganisms, interfering with the binding of aminoacyl-tRNA to the 30S subunit, preventing aminoacyl-tRNA from entering the codon on the mRNA, and inhibiting the elongation of the peptide chain during protein synthesis. Chlortetracycline can also prevent the release of the synthesized protein peptide chain.

Chlortetracycline Premix is approved by regulatory authorities for veterinary use and has been assigned two different approval numbers: Veterinary Drug License No. 050374651 and Veterinary Drug License No. 050374652.

The product is indicated for the treatment of post-weaning piglet diarrhea, swine asthma, and proliferative enteritis. It is recommended to be used under the guidance of a veterinarian, and the dosage should be adjusted according to the severity of the disease and the weight of the animal.

Chlortetracycline Premix is a widely used veterinary drug that has been in use for more than 50 years. It has been extensively studied for its safety and efficacy, and has been shown to be effective in controlling various bacterial infections in animals. However, like all drugs, it can have some side effects, and care should be taken to use it appropriately and responsibly to avoid any adverse effects on animal health and welfare.